Crispr Therapeutics AG (CRSP) — Cash Flow Quality Index
Crispr Therapeutics AG (CRSP) has a Cash Flow Quality Index of -1.08x as of December 2023. Operating cash flow of $-96.07 Million is below net income of $89.35 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore Crispr Therapeutics AG (CRSP) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Crispr Therapeutics AG Cash Flow Quality Index (2019–2021)
Historical Cash Flow Quality Index for Crispr Therapeutics AG across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see CRSP cash flow metrics.
Annual Cash Flow Quality Index for Crispr Therapeutics AG (2019–2021)
Year-by-year earnings quality comparison for Crispr Therapeutics AG.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2021 | 1.43x | $538.97 Million | $377.66 Million | ▲ +68.3% |
| 2019 | 0.85x | $56.68 Million | $66.86 Million | — |